SCHEMBL2927596

SCHEMBL2927596

CCOC(=O)c1c(NC(C)=O)sc2c1CCCC2=O

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 10/20 0.71
USP2 O75604 2/20 0.71
MAPK1 P28482 1/20 0.71
HTT P42858 1/20 0.71
TDP1 Q9NUW8 1/20 0.71
MAPT P10636 5/20 0.60
SMN1; SMN2 Q16637 2/20 0.58
LMNA P02545 2/20 0.58
TSHR P16473 6/20 0.56
GAA P10253 1/20 0.56
NPSR1 Q6W5P4 3/20 0.53
HSD17B10 Q99714 2/20 0.53
ALOX15 P16050 1/20 0.53
KMT2A Q03164 3/20 0.52
MEN1 O00255 2/20 0.52
HPGD P15428 2/20 0.52
ATM Q13315 1/20 0.51
KDM4E B2RXH2 5/20 0.50
TLR2 O60603 4/20 0.49
TLR1 Q15399 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21597594 0.86 ALDH1A1 (0.61) ALDH1A1USP2MAPK1HTTTDP1
SCHEMBL31459942 0.86 ALDH1A1 (0.61) ALDH1A1USP2MAPK1HTTTDP1
SCHEMBL8288610 0.85 ALDH1A1 (0.69) ALDH1A1USP2MAPK1HTTTDP1
SCHEMBL13779376 0.83 ALDH1A1 (0.81) ALDH1A1MAPTSMN1; SMN2LMNATSHR
SCHEMBL3993545 0.83 ALDH1A1 (0.71) ALDH1A1USP2TDP1MAPTSMN1; SMN2
SCHEMBL3992021 0.82 ALDH1A1 (0.83) ALDH1A1USP2MAPK1HTTTDP1
SCHEMBL14076494 0.81 ALDH1A1 (0.65) ALDH1A1USP2MAPK1HTTTDP1
SCHEMBL16290045 0.81 KDM4E (0.50) ALDH1A1USP2MAPK1HTTTDP1
SCHEMBL3915483 0.81 ALDH1A1 (0.82) ALDH1A1USP2MAPK1HTTTDP1
SCHEMBL2306161 0.81 MAPT (0.76) ALDH1A1MAPTSMN1; SMN2LMNATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250255847-A1 SIMMPYRAs: Novel Drugs for Triple Negative Breast Cancer SIMMARON RSEARCH INC 2025-08-14 US disclosed
US-20250154163-A1 Pyrimidinone-Containing 17-Beta-Hydroxysteroid Dehydrogenase Type 13 Inhibitors ENANTA PHARMACEUTICALS, INC. 2025-05-15 US disclosed
WO-2025090868-A1 PYRIMIDINONE-CONTAINING 17-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 13 INHIBITORS ENANTA PHARMACEUTICALS, INC. (US) 2025-05-01 WO disclosed
US-10954222-B2 Benzothiophene compound, alternative autophagy-inducing agent and anticancer agent including the compound as active ingredient, and method for screening for compound having anticancer activity NATIONAL UNIVERSITY CORPORATION TOKYO MEDICAL AND DENTAL UNIVERSITY (JP) 2021-03-23 US disclosed
US-10954222-B2 Benzothiophene compound, alternative autophagy-inducing agent and anticancer agent including the compound as active ingredient, and method for screening for compound having anticancer activity NATIONAL UNIVERSITY CORPORATION TOKYO MEDICAL AND DENTAL UNIVERSITY (JP) 2021-03-23 US disclosed
EP-2813226-B1 BENZOTHIOPHENE COMPOUND, ALTERNATIVE AUTOPHAGY-INDUCING AGENT AND ANTICANCER DRUG INCLUDING BENZOTHIOPHENE COMPOUND AS ACTIVE INGREDIENT NAT UNIV CORP TOKYO MED & DENT (JP) 2016-11-09 EP disclosed
EP-2813226-B1 BENZOTHIOPHENE COMPOUND, ALTERNATIVE AUTOPHAGY-INDUCING AGENT AND ANTICANCER DRUG INCLUDING BENZOTHIOPHENE COMPOUND AS ACTIVE INGREDIENT NAT UNIV CORP TOKYO MED & DENT (JP) 2016-11-09 EP disclosed
US-20150056141-A1 BENZOTHIOPHENE COMPOUND, ALTERNATIVE AUTOPHAGY-INDUCING AGENT AND ANTICANCER AGENT INCLUDING THE COMPOUND AS ACTIVE INGREDIENT, AND METHOD FOR SCREENING FOR COMPOUND HAVING ANTICANCER ACTIVITY NATIONAL UNIVERSITY CORPORATION TOKYO MEDICAL AND DENTAL UNIVERSITY (JP) 2015-02-26 US disclosed
US-20150056141-A1 BENZOTHIOPHENE COMPOUND, ALTERNATIVE AUTOPHAGY-INDUCING AGENT AND ANTICANCER AGENT INCLUDING THE COMPOUND AS ACTIVE INGREDIENT, AND METHOD FOR SCREENING FOR COMPOUND HAVING ANTICANCER ACTIVITY NATIONAL UNIVERSITY CORPORATION TOKYO MEDICAL AND DENTAL UNIVERSITY (JP) 2015-02-26 US disclosed
US-20150056141-A1 BENZOTHIOPHENE COMPOUND, ALTERNATIVE AUTOPHAGY-INDUCING AGENT AND ANTICANCER AGENT INCLUDING THE COMPOUND AS ACTIVE INGREDIENT, AND METHOD FOR SCREENING FOR COMPOUND HAVING ANTICANCER ACTIVITY NATIONAL UNIVERSITY CORPORATION TOKYO MEDICAL AND DENTAL UNIVERSITY (JP) 2015-02-26 US disclosed
EP-2009011-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2008-12-31 EP disclosed
US-7465739-B2 Compounds and their use in therapy SOLVAY PHARMACEUTICALS B.V. (NL) 2008-12-16 US disclosed
US-7465739-B2 Compounds and their use in therapy SOLVAY PHARMACEUTICALS B.V. (NL) 2008-12-16 US disclosed
US-7465739-B2 Compounds and their use in therapy SOLVAY PHARMACEUTICALS B.V. (NL) 2008-12-16 US disclosed
US-7217723-B2 Substituted benzothiophenes, e.g., 7Z)-7-hydroxyimino-4,5,6,7-tetrahydro-benzo[b]thiophene-3-sulfonic acid [2-(4-fluorophenyl)-2-hydroxyethyl]-methyl-amide; treating allergies such as atopic dermatitis, allergic coryza, bronchial asthma, hypersensitive pneumoniac and pulmonary aspergillosis. EISAI CO., LTD. (JP) 2007-05-15 US disclosed
EP-1635839-A2 BENZO[4,5]THIENO[2,3-D]PYRIMIDIN-4-ONES AND THEIR USE IN THERAPY Solvay Pharmaceuticals B.V. (NL) 2006-03-22 EP disclosed
US-20050227959-A1 Heterocyclic compound having oxime group EISAI CO., LTD. (JP) 2005-10-13 US disclosed
US-20050176742-A1 Novel compounds and their use in therapy SOLVAY PHARMACEUTICALS B.V. (NL) 2005-08-11 US disclosed
WO-2005032527-A2 BENZO (4, 5) THIENO (2, 3-D) PYRIMIDIN-4-ONES AND THEIR USE IN THERAPY SOLVAY PHARMACEUTICALS B.V. (NL) 2005-04-14 WO disclosed
US-20050038053-A1 Novel compounds and their use in therapy SOLVAY PHARMACEUTICALS B.V. (NL) 2005-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150056141-A1 BENZOTHIOPHENE COMPOUND, ALTERNATIVE AUTOPHAGY-INDUCING AGENT AND ANTICANCER AGENT INCLUDING THE COMPOUND AS ACTIVE INGREDIENT, AND METHOD FOR SCREENING FOR COMPOUND HAVING ANTICANCER ACTIVITY TFEB, SQSTM1, ATG7 ALDH1A1 1947/4885USP2 2003/4885MAPK1 2838/4885
US-10954222-B2 Benzothiophene compound, alternative autophagy-inducing agent and anticancer agent including the compound as active ingredient, and method for screening for compound having anticancer activity TFEB, SQSTM1, ATG7 ALDH1A1 1947/4885USP2 2003/4885MAPK1 2838/4885
US-20050176742-A1 Novel compounds and their use in therapy HSD17B11, HSD17B2, HSD17B1 ALDH1A1 229/4885USP2 1772/4885MAPK1 3587/4885
US-20050038053-A1 Novel compounds and their use in therapy HSD17B11, HSD17B2, HSD17B1 ALDH1A1 229/4885USP2 1772/4885MAPK1 3587/4885
US-20050227959-A1 Heterocyclic compound having oxime group STAT6, HRH4, HRH2 ALDH1A1 1391/4885USP2 3284/4885MAPK1 755/4885
US-20250154163-A1 Pyrimidinone-Containing 17-Beta-Hydroxysteroid Dehydrogenase Type 13 Inhibitors HSD17B13, HSD17B1, HSD11B1 ALDH1A1 106/4885USP2 3747/4885MAPK1 2362/4885
US-20250255847-A1 SIMMPYRAs: Novel Drugs for Triple Negative Breast Cancer STAT3, STAT6, STAT1 ALDH1A1 2950/4885USP2 1901/4885MAPK1 575/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.